Europe Injection Pen Market

The Europe injection pen market is expected to grow from US$ 11,194.60 million in 2022 to US$ 16,749.04 million by 2028. It is estimated to register a CAGR of 6.9% from 2022 to 2028.

Rising Prevalence of Chronic Disorders in Europe Injection Pen Market

The aging population and changes in social behavior contribute to a few common and costly long-term health problems. According to the World Health Organization (WHO), the prevalence of chronic lifestyle diseases is projected to reach 57% by 2026. With growing urbanization, people are more inclined toward a sedentary lifestyle, which results in obesity and diabetes. Diabetes is one of the biggest global health problems of the 21st century. The increase in disease prevalence is expected to be ~35% over the predicted period. Furthermore, other chronic conditions such as osteoporosis, cardiovascular disorders, and multiple sclerosis require frequent drug administration for treatment and disease management. As per the WHO, cardiovascular disorders are the leading cause of death; nearly 17.9 million deaths are reported every year due to cardiovascular disorders. It has become a new standard for injectable drug delivery among a large patient population on a global level. Moreover, it can be easily used by a large patient population with minimal training with does not require constant assistance from healthcare professionals, owing to which injection pens are largely adopted in home healthcare settings.

Europe Injection Pen Market Overview

The Europe injection pen market is segmented into Germany, France, Italy, Spain, the UK, and the Rest of Europe. The region occupies a significant position in the global injection pen market and is expected to record a promising growth rate during the forecast period. The key drivers for this market are the increased use of biosimilars and other therapeutic agents and the surge in the number of patients suffering from diabetes, cardiovascular disorders, cancer, and fertility issues. Additionally, the rising trend of home healthcare and self-administration of drugs are expected to propel the growth of the injection pen market. Moreover, increase in R&D activities and new product launches are expected to contribute to the growth of the injection pen market during the forecast period.

Europe Injection Pen Market Revenue and Forecast to 2028 (US$ Million)

Europe Injection Pen Market Segmentation

The Europe injection pen market is segmented on the basis of type, therapy, end user, and country. Based on type, the injection pen market is segmented into disposable injection pens and reusable injection pens. The disposable injection pens segment registered a larger market share in 2022.

Based on therapy, the Europe injection pen market is segmented into diabetes therapy, growth hormone therapy, autoimmune diseases therapy, fertility therapy, cancer therapy, and others. The diabetes therapy segment registered the largest market share in 2022.

Based on end user, the Europe injection pen market is segmented into hospitals & clinics, home care, and others. The home care segment registered the largest market share in 2022.

Based on country, the Europe injection pen market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The Rest of Europe dominated the market in 2022.

AstraZeneca Plc, Becton Dickinson and Co, Eli Lilly and Co, Gerresheimer AG, Haselmeier GmbH, Merck KGaA, Novo Nordisk AS, Owen Mumford Ltd, Sanofi SA, and Teva Pharmaceutical Industries Ltd are among the leading companies operating in the Europe injection pen market.

Europe Injection Pen Market Strategic Insights

Europe Injection Pen Market Segmentation Analysis

Europe Injection Pen Market Report Highlights

Europe Injection Pen Report Scope

Europe Injection Pen Market Country and Regional Insights